THE TAPE

Ligand Pharmaceuticals Inc.

$301.71▼ −2.29%
Last close
Relative strength
87RS
of 99, against every stock▲ +3 on the month
Powering up
Unconfirmed
+30.7%
six months against Pharmaceutical Preparations
52-week range
−7.6%
from the high
$175.89$326.63
Setup
blue skyforming
−7.6%
against the pivot at $326.63
No report date on the calendar.
Growth WEAKProof PENDING
Quarter to Sep 30, revenue −32% on a year ago
11/16 O 311.51 H 313.75 L 300.55 Vol 191.3K
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

The four are not in order. That is a description of where the averages sit, not a view about what happens next.

RS87
vs pivot−7.63%
Tightening0.99×
Dry-up1.09×
Up/down vol0.02
From high8%
forming5 of 9checks
Previous breakout trailed out ▲ +15.85% in Jun
Powering up
Support and resistance
Support below
$295.95
-1.9% · tested 4× · last 7 sessions ago
Resistance above
$305.02
+1.1% · tested 4× · last 10 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

The base has run 18.6 weeks and fell 17% from its ceiling at its deepest. The pivot is $326.63, and the stock closed 7.6% below it. Its relative strength rating is 87.

Against its industry
UnconfirmedNone of the patterns above holds.
One month against its industry
-2.3%
Three months against its industry
+21.2%
Six months against its industry
+30.7%

Read against an equal-weighted index of Pharmaceutical Preparations, which is +10.9% against the S&P 500 over six months Partly aligned.

Also on
Peers
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 4.0% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$253.8M
-31.8% year on year
Operating margin
10.1%
Net margin
20.3%
Free cash flow
$90.6M
1.5% of market cap
Price to sales
23.7×
Price to earnings
116.9×

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Oct 29
Key takeaway
Shrinking and burning cash: the quarter weakens the case.
Revenue
$78.7M
+23.6% QoQ · -31.8% YoY
Gross margin
—
Net income
−$28.5M
Loss
Free cash flow
−$27.7M
Burning · 2q runway

What the numbers say

  • Weak: Revenue -31.8% year over year, +23.6% on the quarter
  • Weak: Net loss $28M
  • Weak: Burning cash: operating cash flow -$28M, free cash flow -$28M, worse than $24M last quarter · 2 quarters of cash at this burn
  • Weak: Growth externally funded: capex $142K against operating cash flow -$28M
  • Weak: Net debt $1.07B · cash $56M
Revenue by quarter
Free cash flow
Net income
shares -3.2% in a year · net debt $1.1B

What is not obvious

  • Weak: Stock compensation $18M added back against negative operating cash flow
  • Weak: Interest $3M a quarter against an operating loss: the debt is carried by the balance sheet, not operations

The desk’s own read

Flagged as drifting down since the report

Final read
Growth: WEAK · Economic proof: PENDING
Key question: What turns the cash flow positive?
The next test is revenue growth: revenue -31.8% year over year, +23.6% on the quarter.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 1 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 trimmed.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
GappedTape · 2026-11-06
-5.4%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Moved 5%+ down on earningsTape · 2026-11-06
-5.4% on earnings 2026-11-05
No measurable effect: stocks behave like random ones over the next three sessions (665 cases over 44 nights).
Earnings comingEvent · 2026-10-28
reports 2026-10-29 bmo
No measurable effect: stocks behave like random ones over the next three sessions (2,970 cases over 40 nights).

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news

No headlines for this company in the last couple of weeks.

Insiders
Bought on the open market
0
Sold on the open market
72
$27,108,262 total

Sold: KOZARICH JOHN W, Zimmermann Martine, Aryeh Jason, Reardon Andrew, Espinoza Octavio, Haas Jason, Sabba Stephen L, LAMATTINA JOHN L.

Not counted above: 25 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-11-12 KOZARICH JOHN W · Directorsell500$162,500
2026-11-12 Zimmermann Martine · Directorsell2,000$636,336
2026-11-10 Aryeh Jason · Directorsell844$270,076
2026-11-10 Aryeh Jason · Directorsell646$206,720
2026-11-10 Aryeh Jason · Directorsell10$3,200
2026-11-10 Aryeh Jason · Directorsell500$160,100
2026-11-04 Aryeh Jason · Directorsell282$90,237
2026-11-02 Aryeh Jason · Directorsell700$224,298

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

The geometry
Level · ceiling$325.89
Wrong below$294.66
Measured target · a squeeze has no height to projectnone
Through to the apex35%
Leaning · and easingdown
Length1.6 weeks

Leaning is where price has been sitting against its own range while the range was quiet. It is not a forecast of which way the range opens up, and this site has no measurement that would support one.

What lines up

5 of 9 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
Range tightening through the base
Volume drying up through the base
More up-volume than down-volume
Within 15% of its 52-week high
What analysts expect
Strong buy3
Buy8
Hold0
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray
19w · 17%

The most recent of 3 completed bases.

Checking your subscription…

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Ligand Pharmaceuticals Inc. (LGND) — The Tape